Supply Concerns As India Fast Tracks COVID-19 Vaccines Approved By Certain Regulators
Private Sales Likely But Will Pricing Be Sticking Point?
Executive Summary
In an unusual move prompted by an enormous second wave of infections, India is accelerating approvals for COVID-19 vaccines granted emergency use authorizations by other selected regulators or on the WHO’s emergency use list without a local bridging study. While this seems a prelude to permitting private sales, where will the supplies come from?
You may also be interested in...
As Delta Plus Variant Identified, Changes To India’s Trials Policy Could Help
As a new Delta plus variant is identified, India’s exemption of bridging trials for imported COVID-19 vaccines could help speed up immunization efforts. The urgency to fully immunize individuals could also prompt a reduction in the interval between Serum/AstraZeneca’s COVID-19 vaccine doses
MSD Licenses Molnupiravir In India
MSD India outlines further specifics around the just-announced voluntary licensing deal for molnupiravir with Indian firms, noting an expectation to discuss local data needs with the country’s regulator. All eyes are also on whether non-licensee Natco will stay the course for its application for the investigational antiviral.
Molnupiravir India Licenses: Nuances, Local Data In Focus
MSD-India Region chief outlines further specifics around the just-announced voluntary licensing deal for molnupiravir with Indian firms, noting an expectation to discuss local data needs with the country’s regulator. All eyes are also on whether non-licensee Natco will stay the course for its application for the investigational antiviral.